In metastatic osteosarcoma (OS), a cancer with a high degree of genome instability, treatment with several CDK12 inhibitors led to the sensitivity of OS cell lines and a decrease in metastatic cell outgrowth in the lungs, perhaps partly due to the defective expression of DNA damage response genes (117). Here, CDK12 is linked to cancer.